Methylenedioxymetamfetamine - PharmaTher
Alternative Names: 3,4-methylenedioxy-methamphetamine - PharmaTher; MDMA - PharmaTherLatest Information Update: 28 Feb 2026
At a glance
- Originator PharmaTher
- Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Mental disorders
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for preclinical development in Mental-disorders in Canada (Transdermal, Patch)
- 05 Jan 2022 Preclinical trials in Mental disorders in Canada (Transdermal) as of January 2022 (PharmaTher pipeline, January 2022)
- 14 Dec 2021 Methylenedioxymetamfetamine is available for licensing as of 14 Dec 2021. https://www.pharmather.com/contact.html